Heart Test Labs Clinical Trial Within the Canadian Healthcare System
Heart Test Laboratories, Inc., Colleyville, Texas has entered into a Clinical trial to investigate the early detection of cardiovascular disease and structural abnormalities of the heart with a Canadian Aboriginal population. This trial is being conducted at the Southwest Ontario Aboriginal Health Access Center with the Principal Investigator, Dr. M. Vreugdenhil and Co-Investigator, Dr. M. Weingert.
Colleyville, TX, February 28, 2013 --(PR.com)-- Heart Test Laboratories, Inc., has entered into a Clinical trial to investigate the early detection of cardiovascular disease and structural abnormalities of the heart with a Canadian Aboriginal population. This trial is being conducted at the Southwest Ontario Aboriginal Health Access Center with the Principal Investigator, Dr. M. Vreugdenhil and Co-Investigator, Dr. M. Weingert. While the Aboriginal population is a small percentage of the total Canadian population, they represent a disproportionate amount of disease state due to lower socio economic status. Diabetes and cardiovascular disease are the leading health issues affecting the Canadian Aboriginal population. In general, cardiovascular disease in Canada, represents the largest economic burden on the healthcare system.
This particular situation presents an ideal venue for the utilization of the company’s MyoVista heart screening device. As a quick, non-invasive test, the MyoVista can provide an immediate assessment of cardiac health. Based on this information, the clinician can determine the next course of diagnosis or intervention if needed. The trial also satisfies the statistical requirements of the study. The clinical evaluation is expected to take 6 months and involve approximately 200 patients. It is obviously an outstanding opportunity to demonstrate the overall effectiveness, speed and ease of use of the MyoVista within a very important segment of the Canadian healthcare system.
The MyoVista is a novel electrocardiographic screening device. The clinical set up of the MyoVista is identical to that of a traditional ECG but it obtains and processes signal information in a way that permits much greater resolution of the electrical activity associated with the myocardium (iECG). This technology, property of Heart Test Laboratories, Inc allows analysis of the entire myocardium and provides visual indicators and waveforms for clinical evaluation.
About Heart Test Laboratories
Heart Test Laboratories, founded in 2008 by Dr Guangren (Gary) Chen, MD, is a US based C-Corp company based in Texas. Dr. Chen’s team of researchers developed MyoVista technology as a tool for screening the many thousands of patients that present to clinics with varying cardiac symptoms, ensuring these patients received effective treatment in a timely manner.
It became evident that the benefits of an accurate cardiac screening device extended beyond the hospital walls. Primary Care physicians clinics, athletic programs, and many other settings, where the ability to screen individuals who outwardly present as healthy but that might have an unknown cardiac risk or abnormality, can benefit the MyoVista. The MyoVista’s accuracy in detecting cardiac problems, low cost of purchase/operation, and ease of use exemplifies Heart Test Laboratories’ desire to see world-class technology made available to the entire world. www.HeartTestLabs.com
Notes to editors:
Images are available to accompany this release. Please contact Tess Jackovich at Heart Test Laboratories: E-mail: tessjackovich@hearttestlabs.com
This particular situation presents an ideal venue for the utilization of the company’s MyoVista heart screening device. As a quick, non-invasive test, the MyoVista can provide an immediate assessment of cardiac health. Based on this information, the clinician can determine the next course of diagnosis or intervention if needed. The trial also satisfies the statistical requirements of the study. The clinical evaluation is expected to take 6 months and involve approximately 200 patients. It is obviously an outstanding opportunity to demonstrate the overall effectiveness, speed and ease of use of the MyoVista within a very important segment of the Canadian healthcare system.
The MyoVista is a novel electrocardiographic screening device. The clinical set up of the MyoVista is identical to that of a traditional ECG but it obtains and processes signal information in a way that permits much greater resolution of the electrical activity associated with the myocardium (iECG). This technology, property of Heart Test Laboratories, Inc allows analysis of the entire myocardium and provides visual indicators and waveforms for clinical evaluation.
About Heart Test Laboratories
Heart Test Laboratories, founded in 2008 by Dr Guangren (Gary) Chen, MD, is a US based C-Corp company based in Texas. Dr. Chen’s team of researchers developed MyoVista technology as a tool for screening the many thousands of patients that present to clinics with varying cardiac symptoms, ensuring these patients received effective treatment in a timely manner.
It became evident that the benefits of an accurate cardiac screening device extended beyond the hospital walls. Primary Care physicians clinics, athletic programs, and many other settings, where the ability to screen individuals who outwardly present as healthy but that might have an unknown cardiac risk or abnormality, can benefit the MyoVista. The MyoVista’s accuracy in detecting cardiac problems, low cost of purchase/operation, and ease of use exemplifies Heart Test Laboratories’ desire to see world-class technology made available to the entire world. www.HeartTestLabs.com
Notes to editors:
Images are available to accompany this release. Please contact Tess Jackovich at Heart Test Laboratories: E-mail: tessjackovich@hearttestlabs.com
Contact
Heart Test Labs
Drew Diaz
817.886.9920
www.hearttestlabs.com
Tess Jackovich
tessjackovich@hearttestlabs.com
Drew Diaz
817.886.9920
www.hearttestlabs.com
Tess Jackovich
tessjackovich@hearttestlabs.com
Contact
Categories